{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:57:16Z","timestamp":1790841436123,"version":"4.1.0"},"reference-count":317,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.intimp.2026.116454","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:20:36Z","timestamp":1772853636000},"page":"116454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Drugs and natural bioactive products in modulation of inflammatory pathways in cancer: preclinical and clinical evidence of inflammasomes, cytokine networks, and macrophage polarization"],"prefix":"10.1016","volume":"176","author":[{"given":"Sarvenaz","family":"Parsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe Orak","family":"Sarkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Monzavi","family":"Chaleshtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Darash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiseh","family":"Fotros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia Majidi","family":"Iraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Zahra","family":"Ehsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman Mofidian","family":"Naeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Yahyazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Fatehpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/0019-509X.200658","article-title":"Cancer and cure: a critical analysis","volume":"53","author":"Roy","year":"2016","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.intimp.2026.116454_bb0015","unstructured":"E NK, Koutras A, Syllaios A, Schizas D, Kalagasidou S, Pagkalos A, et al. Basic principles of molecular biology of cancer cell-Molecular cancer indicators. J. BUON 2021;26(5):1723-34."},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0020","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12967-025-06583-3","article-title":"Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches","volume":"23","author":"Bakrim","year":"2025","journal-title":"J. Transl. Med."},{"issue":"24","key":"10.1016\/j.intimp.2026.116454_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415482","article-title":"Antioxidant, anti-inflammatory, anti-menopausal, and anti-cancer effects of lignans and their metabolites","volume":"23","author":"Jang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb0045","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.bcp.2010.07.021","article-title":"Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116454_bb0050","doi-asserted-by":"crossref","first-page":"1083788","DOI":"10.3389\/fimmu.2022.1083788","article-title":"Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116454_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2019.125124","article-title":"Anti-inflammatory effects of flavonoids","volume":"299","author":"Maleki","year":"2019","journal-title":"Food Chem."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12943-025-02243-8","article-title":"Inflammation in cancer: therapeutic opportunities from new insights","volume":"24","author":"Xie","year":"2025","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0065","first-page":"283","article-title":"Cancer initiation and progression: involvement of stem cells and the microenvironment","volume":"1775","author":"Tysnes","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"4260","key":"10.1016\/j.intimp.2026.116454_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.116454_bb0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.apcsb.2019.09.004","article-title":"Interplay between inflammation and cancer","volume":"119","author":"Khandia","year":"2020","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.intimp.2026.116454_bb0080","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fimmu.2017.01132","article-title":"Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development","volume":"8","author":"Kantono","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2326-6066.CIR-16-0269","article-title":"Inflammasomes and Cancer","volume":"5","author":"Karki","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.intimp.2026.116454_bb0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.semcancer.2020.09.013","article-title":"Inflammasomes in cancer: Effect of epigenetic and autophagic modulations","volume":"83","author":"Mishra","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2026.116454_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/cells10092172","article-title":"Inflammasomes and colorectal cancer","volume":"10","author":"Keshavarz Shahbaz","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116454_bb0100","first-page":"1","article-title":"Cytokine-driven cancer immune evasion mechanisms","volume":"396","author":"Arenas","year":"2025","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4110\/in.2017.17.4.214","article-title":"Cytokine signaling in tumor progression","volume":"17","author":"Lee","year":"2017","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2026.116454_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116930","article-title":"Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116454_bb0120","doi-asserted-by":"crossref","first-page":"1103149","DOI":"10.3389\/fonc.2023.1103149","article-title":"Tumor-associated macrophage polarization in the inflammatory tumor microenvironment","volume":"13","author":"Zou","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41577-024-00995-w","article-title":"Mechanistic insights from inflammasome structures","volume":"24","author":"Fu","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.374","article-title":"Pyroptosis and inflammasomes in cancer and inflammation","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0135","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bpa.12479","article-title":"What do we know about the inflammasome in humans?","volume":"27","author":"Amin","year":"2017","journal-title":"Brain Pathol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0140","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ijms22020872","article-title":"Structure, activation and regulation of NLRP3 and AIM2 inflammasomes","volume":"22","author":"Sharma","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imr.12286","article-title":"Initiation and perpetuation of NLRP3 inflammasome activation and assembly","volume":"265","author":"Elliott","year":"2015","journal-title":"Immunol. Rev."},{"issue":"50","key":"10.1016\/j.intimp.2026.116454_bb0150","doi-asserted-by":"crossref","first-page":"41732","DOI":"10.1074\/jbc.M112.381228","article-title":"Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein","volume":"287","author":"Vajjhala","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"47","key":"10.1016\/j.intimp.2026.116454_bb0155","doi-asserted-by":"crossref","first-page":"32932","DOI":"10.1074\/jbc.M109.024273","article-title":"Structure and interdomain dynamics of apoptosis-associated speck-like protein containing a CARD (ASC)","volume":"284","author":"de Alba","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0160","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","article-title":"MCC950 closes the active conformation of NLRP3 to an inactive state","volume":"15","author":"Tapia-Abell\u00e1n","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.intimp.2026.116454_bb0165","doi-asserted-by":"crossref","first-page":"1195572","DOI":"10.3389\/fimmu.2023.1195572","article-title":"The roles of inflammasomes in cancer","volume":"14","author":"Deng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116454_bb0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coi.2019.04.015","article-title":"The NLRP1 inflammasome: new mechanistic insights and unresolved mysteries","volume":"60","author":"Mitchell","year":"2019","journal-title":"Curr. Opin. Immunol."},{"issue":"6528","key":"10.1016\/j.intimp.2026.116454_bb0175","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd0811","article-title":"Human NLRP1 is a sensor for double-stranded RNA","volume":"371","author":"Bauernfried","year":"2021","journal-title":"Science"},{"issue":"7237","key":"10.1016\/j.intimp.2026.116454_bb0180","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature07725","article-title":"AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC","volume":"458","author":"Hornung","year":"2009","journal-title":"Nature"},{"issue":"7517","key":"10.1016\/j.intimp.2026.116454_bb0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13449","article-title":"Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome","volume":"513","author":"Xu","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0190","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.4049\/jimmunol.1102272","article-title":"Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia","volume":"188","author":"Gavrilin","year":"2012","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0195","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2007.08.029","article-title":"Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants","volume":"28","author":"Yu","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2026.116454_bb0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.abb.2019.02.008","article-title":"NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways","volume":"670","author":"Platnich","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0205","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/ijms22041506","article-title":"Regulation, activation and function of caspase-11 during health and disease","volume":"22","author":"Agnew","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116454_bb0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fimmu.2017.00036","article-title":"Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation","volume":"8","author":"Pellegrini","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116454_bb0215","article-title":"Role of the NLRP3 inflammasome: insights into cancer hallmarks","volume":"11","author":"Lin","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.immuni.2010.03.003","article-title":"The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis","volume":"32","author":"Zaki","year":"2010","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0225","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1084\/jem.20181218","article-title":"Host conditioning with IL-1\u03b2 improves the antitumor function of adoptively transferred T cells","volume":"216","author":"Lee","year":"2019","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0230","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3892\/or.2016.4569","article-title":"Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells","volume":"35","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"issue":"24","key":"10.1016\/j.intimp.2026.116454_bb0235","doi-asserted-by":"crossref","first-page":"10161","DOI":"10.1158\/0008-5472.CAN-10-1921","article-title":"The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells","volume":"70","author":"van Deventer","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0240","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00432-024-05625-5","article-title":"Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2\/STAT3 pathway","volume":"150","author":"Zhang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0245","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.4049\/jimmunol.1402098","article-title":"The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis","volume":"194","author":"Williams","year":"2015","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb0250","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.18632\/aging.202620","article-title":"Low expression of NLRP1 is associated with a poor prognosis and immune infiltration in lung adenocarcinoma patients","volume":"13","author":"Shen","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"27","key":"10.1016\/j.intimp.2026.116454_bb0255","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1038\/onc.2017.26","article-title":"NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma","volume":"36","author":"Zhai","year":"2017","journal-title":"Oncogene"},{"issue":"50","key":"10.1016\/j.intimp.2026.116454_bb0260","doi-asserted-by":"crossref","first-page":"21635","DOI":"10.1073\/pnas.1016814108","article-title":"Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4","volume":"107","author":"Hu","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb0265","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1172\/JCI86953","article-title":"NLRC4 suppresses melanoma tumor progression independently of inflammasome activation","volume":"126","author":"Janowski","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb0270","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/hep.30693","article-title":"NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD","volume":"70","author":"Ohashi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0275","doi-asserted-by":"crossref","first-page":"13007","DOI":"10.1038\/ncomms13007","article-title":"Obesity-associated NLRC4 inflammasome activation drives breast cancer progression","volume":"7","author":"Kolb","year":"2016","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0280","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nm.3908","article-title":"Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0285","first-page":"14750","article-title":"The molecular mechanism of breast cancer cell apoptosis induction by absent in melanoma (AIM2)","volume":"8","author":"Liu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0290","doi-asserted-by":"crossref","first-page":"20161","DOI":"10.1002\/jcp.28617","article-title":"AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway","volume":"234","author":"Zhang","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13046-025-03366-y","article-title":"Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential","volume":"44","author":"Singh","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116454_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1133013","article-title":"Mechanism of inflammasomes in cancer and targeted therapies","volume":"13","author":"Gu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116454_bb0305","doi-asserted-by":"crossref","first-page":"1624770","DOI":"10.3389\/fimmu.2025.1624770","article-title":"NLRP3 and beyond: inflammasomes as central cellular hub and emerging therapeutic target in inflammation and disease","volume":"16","author":"Pinz\u00f3n-Fern\u00e1ndez","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0310","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1002\/ptr.7118","article-title":"Medicinal plants and bioactive natural products as inhibitors of NLRP3 inflammasome","volume":"35","author":"Bagherniya","year":"2021","journal-title":"Phytother. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0315","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3565(24)29317-4","article-title":"Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors","volume":"299","author":"Perregaux","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0320","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0325","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00018-017-2720-9","article-title":"Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma","volume":"75","author":"Chen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0330","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00432-020-03274-y","article-title":"The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation","volume":"146","author":"Yaw","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0335","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0340","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb0345","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2000915118","article-title":"Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion","volume":"118","author":"Tengesdal","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0350","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0355","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.1701495","article-title":"Curcumin suppresses IL-1\u03b2 secretion and prevents inflammation through inhibition of the NLRP3 inflammasome","volume":"200","author":"Yin","year":"2018","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0360","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/molecules28020742","article-title":"The effects of curcumin on inflammasome: latest update","volume":"28","author":"Benameur","year":"2023","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0365","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1940-6207.CAPR-13-0259","article-title":"Curcumin: a double hit on malignant mesothelioma","volume":"7","author":"Miller","year":"2014","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0370","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/15384047.2022.2058862","article-title":"Curcumin activates NLRC4, AIM2, and IFI16 inflammasomes and induces pyroptosis by up-regulated ISG3 transcript factor in acute myeloid leukemia cell lines","volume":"23","author":"Zhou","year":"2022","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0375","article-title":"Curcumin: biological activities and modern pharmaceutical forms","volume":"11","author":"Uro\u0161evi\u0107","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0380","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/ph14111068","article-title":"New insights into curcumin- and resveratrol-mediated anti-cancer effects","volume":"14","author":"Arena","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0385","doi-asserted-by":"crossref","first-page":"31737","DOI":"10.1038\/s41598-025-14587-8","article-title":"In vivo mechanisms of resveratrol liposomes in targeting the TLR4\/NLRP3 pathway in lung cancer","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116454_bb0390","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.intimp.2017.06.029","article-title":"Resveratrol alleviates cerebral ischemia\/reperfusion injury in rats by inhibiting NLRP3 inflammasome activation through Sirt1-dependent autophagy induction","volume":"50","author":"He","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116454_bb0395","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuroscience.2017.02.027","article-title":"Resveratrol protects against spinal cord injury by activating autophagy and inhibiting apoptosis mediated by the SIRT1\/AMPK signaling pathway","volume":"348","author":"Zhao","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.intimp.2026.116454_bb0400","first-page":"66","article-title":"Quercetin effectively improves LPS-induced intestinal inflammation, pyroptosis, and disruption of the barrier function through the TLR4\/NF-\u03baB\/NLRP3 signaling pathway in vivo and in vitro. Food","author":"Zhang","year":"2022","journal-title":"Nutr. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0405","doi-asserted-by":"crossref","first-page":"934","DOI":"10.62347\/MKAN3550","article-title":"Quercetin-induced pyroptosis in colon cancer through NEK7-mediated NLRP3 inflammasome-GSDMD signaling pathway activation","volume":"14","author":"Feng","year":"2024","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/nano11102658","article-title":"Nanotechnology innovations to enhance the therapeutic efficacy of quercetin","volume":"11","author":"Pinheiro","year":"2021","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.intimp.2026.116454_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155909","article-title":"Berberine alleviates ulcerative colitis by inhibiting inflammation through targeting IRGM1","volume":"133","author":"Meng","year":"2024","journal-title":"Phytomedicine"},{"issue":"20","key":"10.1016\/j.intimp.2026.116454_bb0420","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.3390\/molecules26206238","article-title":"Inhibitory role of berberine, an isoquinoline alkaloid, on NLRP3 inflammasome activation for the treatment of inflammatory diseases","volume":"26","author":"Sarbadhikary","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0425","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12906-019-2615-4","article-title":"Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell","volume":"19","author":"Yao","year":"2019","journal-title":"BMC Complement. Altern. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0430","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/cancers17020290","article-title":"IL-1\u03b2 in neoplastic disease and the role of its tumor-derived form in the progression and treatment of metastatic prostate cancer","volume":"17","author":"Oyende","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0435","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/0008-5472.CAN-19-2288","article-title":"Breast cancer cell\u2013derived soluble CD44 promotes tumor progression by triggering macrophage IL1\u03b2 production","volume":"80","author":"Jang","year":"2020","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0440","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.molcel.2023.05.011","article-title":"IL-1\u03b2-associated NNT acetylation orchestrates iron-sulfur cluster maintenance and cancer immunotherapy resistance","volume":"83","author":"Han","year":"2023","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb0445","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.4251\/wjgo.v16.i5.1676","article-title":"Interleukin-1\u03b2: Friend or foe for gastrointestinal cancers","volume":"16","author":"Khawkhiaw","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0450","doi-asserted-by":"crossref","first-page":"12732","DOI":"10.1038\/s41598-023-39907-8","article-title":"IL-1\u03b2 transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma","volume":"13","author":"Muthupalani","year":"2023","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0455","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-17-1366","article-title":"Tumor\u2013stroma IL1\u03b2-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0460","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1038\/s41598-023-39487-7","article-title":"Genetic polymorphisms in interleukin-1\u03b2 (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma","volume":"13","author":"Lurje","year":"2023","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112940","article-title":"SOCS3 deletion in effector T cells confers an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine","volume":"42","author":"Mise-Omata","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.116454_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.rvsc.2023.105014","article-title":"Upregulation of miR-21 and pro-inflammatory cytokine genes IL-6 and TNF-\u03b1 in promoting a pro-tumorigenic microenvironment in canine mammary carcinomas","volume":"164","author":"Abbate","year":"2023","journal-title":"Res. Vet. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb0475","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/biomedicines11102623","article-title":"Interleukin-6 in hepatocellular carcinoma: a dualistic point of view","volume":"11","author":"Nenu","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0480","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.tem.2023.08.001","article-title":"The exercise IL-6 enigma in cancer","volume":"34","author":"Orange","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0485","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jcyt.2021.12.005","article-title":"Pancreatic cancer growth promoted by bone marrow mesenchymal stromal cell\u2013derived IL-6 is reversed predominantly by IL-6 blockade","volume":"24","author":"Antoon","year":"2022","journal-title":"Cytotherapy"},{"issue":"20","key":"10.1016\/j.intimp.2026.116454_bb0490","doi-asserted-by":"crossref","first-page":"11027","DOI":"10.3390\/ijms222011027","article-title":"IL-6 in the ecosystem of head and neck cancer: possible therapeutic perspectives","volume":"22","author":"\u0160panko","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0495","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cells11091502","article-title":"Crocin inhibits angiogenesis and metastasis in colon cancer via TNF-\u03b1\/NF-kB\/VEGF pathways","volume":"11","author":"Bakshi","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","article-title":"The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches","volume":"43","author":"Cruceriu","year":"2020","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.intimp.2026.116454_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154928","article-title":"Bruceine D suppresses CAF-promoted TNBC metastasis under TNF-\u03b1 stimulation by inhibiting Notch1-Jagged1\/NF-\u03baB (p65) signaling","volume":"123","author":"Chen","year":"2024","journal-title":"Phytomedicine"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0510","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.7150\/ijbs.61350","article-title":"TNF-\u03b1 augments CXCL10\/CXCR3 axis activity to induce epithelial-mesenchymal transition in colon cancer cell","volume":"17","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"21","key":"10.1016\/j.intimp.2026.116454_bb0515","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.3390\/cancers13215565","article-title":"MicroRNA-21 plays multiple oncometabolic roles in colitis-associated carcinoma and colorectal cancer via the PI3K\/AKT, STAT3, and PDCD4\/TNF-\u03b1 signaling pathways in zebrafish","volume":"13","author":"Lai","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb0520","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/j.intimp.2026.116454_bb0525","doi-asserted-by":"crossref","first-page":"13181","DOI":"10.3390\/ijms222413181","article-title":"Correlation between oxidative stress and transforming growth factor-beta in cancers","volume":"22","author":"Chung","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0530","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jhep.2019.09.012","article-title":"Clathrin switches transforming growth factor-\u03b2 role to pro-tumorigenic in liver cancer","volume":"72","author":"Caballero-D\u00edaz","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2026.116454_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150409","article-title":"The TGF-\u03b21 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro-and anti-tumorigenic effects","volume":"732","author":"Dropmann","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12890-025-03533-z","article-title":"\u03b2-elemene inhibits tumor-promoting in small cell lung cancer by affecting M2 macrophages and TGF-\u03b2","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Pulmon Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0545","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/s41467-021-23048-5","article-title":"Interplay between transforming growth factor-\u03b2 and Nur77 in dual regulations of inhibitor of differentiation 1 for colonic tumorigenesis","volume":"12","author":"Niu","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0550","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028530","article-title":"Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer","volume":"10","author":"Yan","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb0555","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0560","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cancers13020167","article-title":"IL-12 family cytokines in cancer and immunotherapy","volume":"13","author":"Mirlekar","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0565","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00262-018-2280-3","article-title":"Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-\u03b3","volume":"68","author":"Lin","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF-and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0575","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.intimp.2026.116454_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized interleukin-12 for cancer immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0585","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0590","article-title":"At the crossroads of TNF \u03b1 signaling and cancer","volume":"17","author":"Manohar","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116454_bb0595","series-title":"The TNF Superfamily: Methods and Protocols","first-page":"271","article-title":"Methods for evaluation of TNF-\u03b1 inhibition effect","author":"Hira","year":"2020"},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb0600","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41573-024-01053-9","article-title":"Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer","volume":"23","author":"Croft","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0605","doi-asserted-by":"crossref","first-page":"845","DOI":"10.25122\/jml-2021-0359","article-title":"Comparison of TNF-\u03b1 and IL-19 concentrations at different stages of breast cancer","volume":"15","author":"Mohammed","year":"2022","journal-title":"J. Med. Life"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0610","first-page":"1185","article-title":"TNF-\u03b1-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer","volume":"2","author":"Tu","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.intimp.2026.116454_bb0615","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3390\/cells11162524","article-title":"S1P-Induced TNF-\u03b1 and IL-6 Release from PBMCs Exacerbates Lung Cancer-Associated Inflammation","volume":"11","author":"Terlizzi","year":"2022","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.intimp.2026.116454_bb0620","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1182\/blood.2024028239","article-title":"A CEBPB\/IL-1\u03b2\/TNF-\u03b1 feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia","volume":"145","author":"Allen","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0625","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2026.116454_bb0630","doi-asserted-by":"crossref","unstructured":"Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell 2024;187(13):3390-408. e19.","DOI":"10.1016\/j.cell.2024.04.025"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0635","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008386","article-title":"Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer","volume":"12","author":"Gu","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0640","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/2159-8290.CD-21-1181","article-title":"Tumor-derived lysophosphatidic acid blunts protective type I interferon responses in ovarian cancer","volume":"12","author":"Chae","year":"2022","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0645","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ccell.2021.06.018","article-title":"PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity","volume":"39","author":"Gozgit","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0650","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0655","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0660","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL\u20101 and IL\u20101 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0665","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"issue":"18","key":"10.1016\/j.intimp.2026.116454_bb0670","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1158\/0008-5472.CAN-18-0413","article-title":"IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0675","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1474319","article-title":"Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study","volume":"7","author":"Isambert","year":"2018","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb0680","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2217\/fon-2020-1098","article-title":"Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design","volume":"17","author":"Garrido","year":"2021","journal-title":"Future Oncol."},{"issue":"10105","key":"10.1016\/j.intimp.2026.116454_bb0685","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.116454_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2015.12.003","article-title":"Preclinical characterization and clinical development of ILARIS\u00ae(canakinumab) for the treatment of autoinflammatory diseases","volume":"32","author":"Gram","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.intimp.2026.116454_bb0695","series-title":"Ilaris (canakinumab) receives a new indication for the treatment of systemic juvenile idiopathic arthritis","author":"Raedler","year":"2013"},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0700","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0705","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","article-title":"IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer","volume":"22","author":"Neurath","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"issue":"22","key":"10.1016\/j.intimp.2026.116454_bb0710","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.3390\/cells11223698","article-title":"The role of IL-6 in cancer cell invasiveness and metastasis\u2014overview and therapeutic opportunities","volume":"11","author":"Ra\u0161kov\u00e1","year":"2022","journal-title":"Cells"},{"issue":"25","key":"10.1016\/j.intimp.2026.116454_bb0715","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO-25-01631","article-title":"Randomized phase II study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer: survival and cachexia","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7918","key":"10.1016\/j.intimp.2026.116454_bb0720","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-022-04847-2","article-title":"cGAS\u2013STING drives the IL-6-dependent survival of chromosomally instable cancers","volume":"607","author":"Hong","year":"2022","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0725","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","article-title":"A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors","volume":"20","author":"Angevin","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0730","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10637-012-9857-z","article-title":"A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Hudes","year":"2013","journal-title":"Investig. New Drugs"},{"issue":"10302","key":"10.1016\/j.intimp.2026.116454_bb0735","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0740","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0745","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0750","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MEG.0000000000002349","article-title":"SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes","volume":"34","author":"Giannos","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb0755","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3390\/cimb45040189","article-title":"Infliximab inhibits colitis associated cancer in model mice by downregulating genes associated with mast cells and decreasing their accumulation","volume":"45","author":"Wang","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0760","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers16010052","article-title":"Infliximab, a monoclonal antibody against TNF-\u03b1, inhibits NF-\u03baB activation, autotaxin expression and breast cancer metastasis to lungs","volume":"16","author":"Shinde","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0770","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","article-title":"Focal irradiation and systemic TGF\u03b2 blockade in metastatic breast cancer","volume":"24","author":"Formenti","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0775","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro-oncology"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0780","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/ijms19030686","article-title":"Potential health benefits of olive oil and plant polyphenols","volume":"19","author":"Gorzynik-Debicka","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb0785","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0955-2863(02)00208-5","article-title":"Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships","volume":"13","author":"Heim","year":"2002","journal-title":"J. Nutr. Biochem."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0790","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/eji.200425778","article-title":"In vivo quercitrin anti\u2010inflammatory effect involves release of quercetin, which inhibits inflammation through down\u2010regulation of the NF\u2010\u03baB pathway","volume":"35","author":"Comalada","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0795","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/sj.bjp.0704803","article-title":"Inhibition of LPS\u2010stimulated pathways in macrophages by the flavonoid luteolin","volume":"136","author":"Xagorari","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0800","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0952-3278(98)90125-9","article-title":"Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs","volume":"58","author":"Kim","year":"1998","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"issue":"16","key":"10.1016\/j.intimp.2026.116454_bb0805","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/nu16162735","article-title":"Polyphenols in the prevention and treatment of colorectal cancer: A systematic review of clinical evidence","volume":"16","author":"L\u00f3pez-G\u00f3mez","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2026.116454_bb0810","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3389\/fimmu.2019.00729","article-title":"Polyphenols: immunomodulatory and therapeutic implication in colorectal cancer","volume":"10","author":"Mileo","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0815","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s10020-018-0032-7","article-title":"Phyto-polyphenols as potential inhibitors of breast cancer metastasis","volume":"24","author":"Avtanski","year":"2018","journal-title":"Mol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0820","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1872213X13666190426164124","article-title":"Effects of flavonoids and its derivatives on immune cell responses","volume":"13","author":"Mart\u00ednez","year":"2019","journal-title":"Recent Patents Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.intimp.2026.116454_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157053","article-title":"Oroxyloside inhibits liver fibrosis and hepatocarcinogenesis dependent on hepatocyte-specific knockout of Atg5","volume":"145","author":"Liu","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2026.116454_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111017","article-title":"Myricetin: A review of the most recent research","volume":"134","author":"Song","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127282","article-title":"LZ-207, a newly synthesized flavonoid, induces apoptosis and suppresses inflammation-related colon cancer by inhibiting the NF-\u03baB signaling pathway","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.116454_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120752","article-title":"Naringenin: a potential flavonoid phytochemical for cancer therapy","volume":"305","author":"Motallebi","year":"2022","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb0845","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/ptr.5849","article-title":"Morin suppresses astrocyte activation and regulates cytokine release in bone cancer pain rat models","volume":"31","author":"Jiang","year":"2017","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0850","doi-asserted-by":"crossref","DOI":"10.3390\/biom14020200","article-title":"Terpenoid-mediated targeting of STAT3 signaling in cancer: an overview of preclinical studies","volume":"14","author":"Khan","year":"2024","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0855","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-008-0118-y","article-title":"Terpenoids and breast cancer chemoprevention","volume":"115","author":"Rabi","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb0860","doi-asserted-by":"crossref","DOI":"10.3390\/md20060349","article-title":"Natural marine products: anti-colorectal cancer in vitro and in vivo","volume":"20","author":"Han","year":"2022","journal-title":"Mar. Drugs"},{"issue":"22","key":"10.1016\/j.intimp.2026.116454_bb0865","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2174\/1381612827666210211125304","article-title":"Furanodiene: a novel, potent, and multitarget cancer-fighting terpenoid","volume":"27","author":"Batool","year":"2021","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0870","first-page":"280","article-title":"Limonene terpenoid obstructs human bladder cancer cell (T24 cell line) growth by inducing cellular apoptosis, caspase activation, G2\/M phase cell cycle arrest and stops cancer metastasis","volume":"25","author":"Ye","year":"2020","journal-title":"J. BUON"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0875","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","article-title":"Metabolism, metabolites, and macrophages in cancer","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0880","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001341","article-title":"Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer","volume":"9","author":"Li","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0885","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.3390\/ijms24087493","article-title":"Tumor-associated macrophage subsets: shaping polarization and targeting","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb0890","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: can we be more clever than cancer cells?","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"23","key":"10.1016\/j.intimp.2026.116454_bb0895","doi-asserted-by":"crossref","first-page":"11238","DOI":"10.1158\/0008-5472.CAN-06-1278","article-title":"Macrophages regulate the angiogenic switch in a mouse model of breast cancer","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116454_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104119","article-title":"The roles of tumor-associated macrophages in tumor angiogenesis and metastasis","volume":"353","author":"Fu","year":"2020","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0905","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0910","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/biom12030392","article-title":"Therapeutic approaches targeting proteins in tumor-associated macrophages and their applications in cancers","volume":"12","author":"Wu","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2026.116454_bb0915","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1494462","article-title":"Macrophages in tumor cell migration and metastasis","volume":"15","author":"Friedman-DeLuca","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0920","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11912-017-0634-1","article-title":"CSF-1R inhibitor development: current clinical status","volume":"19","author":"Peyraud","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.intimp.2026.116454_bb0925","article-title":"A comprehensive review on targeting diverse immune cells for anticancer therapy: beyond immune checkpoint inhibitors","volume":"104702","author":"Liu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb0930","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"16","key":"10.1016\/j.intimp.2026.116454_bb0935","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb0940","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates t-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb0945","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/cncr.27758","article-title":"Phase 2 trial of linifanib (ABT\u2010869) in patients with unresectable or metastatic hepatocellular carcinoma","volume":"119","author":"Toh","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb0950","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","article-title":"The role of PI3K\u03b3 in the immune system: new insights and translational implications","volume":"22","author":"Lanahan","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"7629","key":"10.1016\/j.intimp.2026.116454_bb0955","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116454_bb0960","doi-asserted-by":"crossref","first-page":"1658795","DOI":"10.3389\/fimmu.2025.1658795","article-title":"Progress in targeting tumor-associated macrophages in cancer immunotherapy","volume":"16","author":"Xia","year":"2025","journal-title":"Front. Immunol."},{"issue":"Spec Feature","key":"10.1016\/j.intimp.2026.116454_bb0965","first-page":"157","article-title":"Zydelig (idelalisib): first-in-class PI3 kinase inhibitor approved for the treatment of 3 hematologic malignancies","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"35","key":"10.1016\/j.intimp.2026.116454_bb0970","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2026.116454_bb0975","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood.2019001795","article-title":"Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb0980","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb0985","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb0990","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/2326-6066.CIR-17-0537","article-title":"Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb0995","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","article-title":"Anti\u2013PD-L1 treatment results in functional remodeling of the macrophage compartment","volume":"79","author":"Xiong","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116454_bb1000","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690869","article-title":"Defects in macrophage reprogramming in cancer therapy: the negative impact of PD-L1\/PD-1","volume":"12","author":"Cai","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","article-title":"Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed","volume":"10","author":"Qu","year":"2022","journal-title":"Biomark. Res."},{"issue":"5473","key":"10.1016\/j.intimp.2026.116454_bb1015","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/hep.27070","article-title":"Blockade of CD47\u2010mediated cathepsin S\/protease\u2010activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma","volume":"60","author":"Lee","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2026.116454_bb1025","article-title":"Targeting the CD47\/SIRP\u03b1 pathway in malignancies: recent progress, difficulties and future perspectives","volume":"14","author":"Jiang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116454_bb1030","series-title":"Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study","author":"Gan","year":"2021"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb1035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2026.116454_bb1040","series-title":"A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors","author":"Burris","year":"2021"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb1045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann. Hematol."},{"issue":"6141","key":"10.1016\/j.intimp.2026.116454_bb1050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","article-title":"Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies","volume":"341","author":"Weiskopf","year":"2013","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb1055","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116454_bb1060","series-title":"Preliminary results of a first-in-human phase I dtudy of IMM01","author":"Sun","year":"2021"},{"key":"10.1016\/j.intimp.2026.116454_bb1065","series-title":"First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies","author":"Roohullah","year":"2021"},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb1070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134728","article-title":"Targeting macrophage checkpoint inhibitor SIRP\u03b1 for anticancer therapy","volume":"5","author":"Liu","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2026.116454_bb1075","series-title":"Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRP\u03b1. MAbs","year":"2019"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jgr.2016.12.012","article-title":"Ginsenoside Rg3 promotes inflammation resolution through M2 macrophage polarization","volume":"42","author":"Kang","year":"2018","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.intimp.2026.116454_bb1085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yjmcc.2015.04.025","article-title":"Curcumin induces M2 macrophage polarization by secretion IL-4 and\/or IL-13","volume":"85","author":"Gao","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb1090","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FJC.0000000000000079","article-title":"Molecular analysis of curcumin-induced polarization of murine RAW264. 7 macrophages","volume":"63","author":"Chen","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116454_bb1095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jnutbio.2018.12.005","article-title":"Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent","volume":"66","author":"Mohammadi","year":"2019","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.intimp.2026.116454_bb1100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.975320","article-title":"Evaluating anticancer properties of Withaferin A\u2014a potent phytochemical","volume":"13","author":"Atteeq","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"06","key":"10.1016\/j.intimp.2026.116454_bb1105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/a-2289-9600","article-title":"The potential pharmacological effects of natural product withaferin A in cancer: opportunities and challenges for clinical translation","volume":"90","author":"Devabattula","year":"2024","journal-title":"Planta Med."},{"key":"10.1016\/j.intimp.2026.116454_bb1110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.colsurfb.2017.04.046","article-title":"Withaferin-A, a steroidal lactone encapsulated mannose decorated liposomes ameliorates rheumatoid arthritis by intriguing the macrophage repolarization in adjuvant-induced arthritic rats","volume":"155","author":"Sultana","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.intimp.2026.116454_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2021.104743","article-title":"(-)-Epigallocatechin-3-gallate (EGCG) modulates polarized macrophages to suppress M1 phenotype and promote M2 polarization in vitro and in vivo","volume":"87","author":"Hu","year":"2021","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.intimp.2026.116454_bb1120","article-title":"Safflower polysaccharide inhibits AOM\/DSS-induced mice colorectal cancer through the regulation of macrophage polarization","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb1125","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/nu11102264","article-title":"Astragalus polysaccharides (PG2) enhances the M1 polarization of macrophages, functional maturation of dendritic cells, and T cell-mediated anticancer immune responses in patients with lung cancer","volume":"11","author":"Bamodu","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2026.116454_bb1130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.743837","article-title":"Baicalein potentiated M1 macrophage polarization in cancer through targeting PI3K\u03b3\/NF-\u03baB signaling","volume":"12","author":"He","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116454_bb1135","doi-asserted-by":"crossref","unstructured":"Forghani P, Khorramizadeh MR, Waller EK. Silibinin inhibits accumulation of myeloid\u2010derived suppressor cells and tumor growth of murine breast cancer. Cancer Med. 2014;3(2):215-24.","DOI":"10.1002\/cam4.186"},{"key":"10.1016\/j.intimp.2026.116454_bb1140","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9549315","article-title":"Screening five Qi-Tonifying herbs on M2 phenotype macrophages","volume":"2019","author":"Jiang","year":"2019","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1145","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1038\/s41598-020-77800-w","article-title":"Targeting macrophage priming by polyphyllin VII triggers anti-tumor immunity via STING-governed cytotoxic T-cell infiltration in lung cancer","volume":"10","author":"Yu","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb1150","first-page":"1551","article-title":"Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4\/NF-\u03baB\/STAT3 signaling pathway","volume":"14","author":"Min","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.intimp.2026.116454_bb1155","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fphar.2019.00624","article-title":"Saikosaponin A inhibits breast cancer by regulating Th1\/Th2 balance","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb1160","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2017.06.071","article-title":"\u03b2-elemene inhibits tumor-promoting effect of M2 macrophages in lung cancer","volume":"490","author":"Yu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2026.116454_bb1165","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.2147\/OTT.S249046","article-title":"Dihydroartemisinin prevents progression and metastasis of head and neck squamous cell carcinoma by inhibiting polarization of macrophages in tumor microenvironment","volume":"13","author":"Chen","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.intimp.2026.116454_bb1170","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5137505","article-title":"Berberine inhibits intestinal polyps growth in Apc (min\/+) mice via regulation of macrophage polarization","volume":"2016","author":"Piao","year":"2016","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb1175","first-page":"4308","article-title":"Matrine suppresses lung cancer metastasis via targeting M2-like tumour-associated-macrophages polarization","volume":"11","author":"Zhao","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb1180","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jphs.2018.07.007","article-title":"Osthole inhibits pancreatic cancer progression by directly exerting negative effects on cancer cells and attenuating tumor-infiltrating M2 macrophages","volume":"137","author":"Wang","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2026.116454_bb1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115015","article-title":"Evaluation of the association of chronic inflammation and cancer: Insights and implications","volume":"164","author":"Nigam","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"14","key":"10.1016\/j.intimp.2026.116454_bb1190","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2003.07.127","article-title":"Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer","volume":"21","author":"Altorki","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb1195","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/bcr3409","article-title":"A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer","volume":"15","author":"Brand\u00e3o","year":"2013","journal-title":"Breast Cancer Res."},{"issue":"17","key":"10.1016\/j.intimp.2026.116454_bb1200","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/cncr.32950","article-title":"Perioperative COX2 and\u00a0\u03b2-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial","volume":"126","author":"Haldar","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb1205","article-title":"The IL-1 antagonist anakinra attenuates glioblastoma aggressiveness by dampening tumor-associated inflammation","volume":"12","author":"H\u00fcbner","year":"2020","journal-title":"Cancers [Internet]"},{"key":"10.1016\/j.intimp.2026.116454_bb1210","doi-asserted-by":"crossref","unstructured":"Pelon M, Krzeminski P, Tracz-Gaszewska Z, Misiewicz-Krzeminska I. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells. Front. Pharmacol. 2024;Volume 15 - 2024.","DOI":"10.3389\/fphar.2024.1351565"},{"key":"10.1016\/j.intimp.2026.116454_bb1215","article-title":"Bridging inflammation and venous thrombosis: the NLRP3 inflammasome connection","volume":"12","author":"Wu","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108589","article-title":"Designing clinical trials for patients who are not average","volume":"27","author":"Yankeelov","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2026.116454_bb1225","doi-asserted-by":"crossref","unstructured":"Landeiro LCG, Martins TdC, Grigolon RB, Monteiro I, Balardin JB, Padilha E, et al. The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review. Front. Pharmacol. 2024;Volume 15 - 2024.","DOI":"10.3389\/fphar.2024.1338546"},{"key":"10.1016\/j.intimp.2026.116454_bb1230","doi-asserted-by":"crossref","unstructured":"Lai H, Liu Y, Wu J, Cai J, Jie H, Xu Y, Deng S. Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics. Front. Pharmacol. 2022;Volume 13 - 2022.","DOI":"10.3389\/fphar.2022.1078766"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1235","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12944-023-01955-4","article-title":"The association of statin therapy and cancer: a meta-analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.intimp.2026.116454_bb1240","doi-asserted-by":"crossref","unstructured":"Liu C, Chen H, Hu B, Shi J, Chen Y, Huang K. New insights into the therapeutic potentials of statins in cancer. Front. Pharmacol. 2023;Volume 14 - 2023.","DOI":"10.3389\/fphar.2023.1188926"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1245","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12967-023-04263-8","article-title":"Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing","volume":"21","author":"Hua","year":"2023","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb1250","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/cancers15123233","article-title":"Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics","volume":"15","author":"Papachristos","year":"2023","journal-title":"Cancers [Internet]"},{"key":"10.1016\/j.intimp.2026.116454_bb1255","doi-asserted-by":"crossref","unstructured":"Racacho KJ, Shiau Y-P, Villa R, Mahri S, Tang M, Lin T-Y, Li Y. The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches. Front. Immunol. 2025;Volume 16 - 2025.","DOI":"10.3389\/fimmu.2025.1621812"},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb1260","first-page":"915","article-title":"Microenvironment and tumor heterogeneity as pharmacological targets in precision oncology","volume":"18","author":"Tonello","year":"2025","journal-title":"Pharm. Int."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb1265","article-title":"Repurposing metformin in precision oncology: mechanistic insights, biomarker-guided strategies, and translational imperatives","volume":"61","author":"Khan","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1270","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116454_bb1275","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-1918","article-title":"FDA-AACR strategies for optimizing dosages for oncology drug products: early phase trials using innovative trial designs and biomarkers","author":"Okusanya","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.intimp.2026.116454_bb1280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713353","article-title":"The impact of metformin on tumor-infiltrated immune cells: preclinical and clinical studies","volume":"24","author":"Abdelmoneim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005940","article-title":"Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models","volume":"11","author":"Kansal","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.intimp.2026.116454_bb1290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1507283","article-title":"CD8(+) T cell exhaustion in the tumor microenvironment of breast cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.intimp.2026.116454_bb1295","doi-asserted-by":"crossref","first-page":"8367","DOI":"10.3390\/molecules27238367","article-title":"Natural products as anticancer agents: current status and future perspectives","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules [Internet]"},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb1300","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/cimb47090716","article-title":"Revisiting curcumin in cancer therapy: recent insights into molecular mechanisms, nanoformulations, and synergistic combinations","volume":"47","author":"Akter","year":"2025","journal-title":"Curr. Issues Mol. Biol. [Internet]"},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb1305","first-page":"1301","article-title":"Resveratrol as a naturally occurring inflammasome modulator: implications for health and disease","volume":"28","author":"Ghasemzadeh Rahbardar","year":"2025","journal-title":"Iran J. Basic Med. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.116454_bb1310","doi-asserted-by":"crossref","DOI":"10.1002\/fsn3.70735","article-title":"Anticancer molecular mechanisms of epigallocatechin gallate: an updated review on clinical trials","volume":"13","author":"Noman","year":"2025","journal-title":"Food Sci. Nutr."},{"issue":"19","key":"10.1016\/j.intimp.2026.116454_bb1315","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.3390\/ijms231911746","article-title":"A comprehensive analysis and anti-cancer activities of quercetin in ros-mediated cancer and cancer stem cells","volume":"23","author":"Biswas","year":"2022","journal-title":"Int. J. Mol. Sci. [Internet]"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb1320","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70643","article-title":"The effects of silibinin combined With EGFR-TKIs in the treatment of NSCLC","volume":"14","author":"Wang","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2026.116454_bb1325","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1592066","article-title":"A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb1330","doi-asserted-by":"crossref","DOI":"10.3390\/nu17040616","article-title":"Polyphenol-based prevention and treatment of cancer through epigenetic and combinatorial mechanisms","volume":"17","author":"Singaravelan","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2026.116454_bb1335","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1587215","article-title":"Plant-based secondary metabolites as natural remedies: a comprehensive review on terpenes and their therapeutic applications","volume":"16","author":"Khanam","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1340","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12935-023-03052-z","article-title":"Synergistic effects of flavonoids and paclitaxel in cancer treatment: a systematic review","volume":"23","author":"Asnaashari","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb1345","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28093746","article-title":"Combination chemotherapy with selected polyphenols in preclinical and clinical studies-an update overview","volume":"28","author":"Jakobu\u0161i\u0107 Brala","year":"2023","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb1350","article-title":"Resveratrol, Epigallocatechin gallate and curcumin for cancer therapy: challenges from their pro-apoptotic properties","volume":"13","author":"Chimento","year":"2023","journal-title":"Life (Basel)"},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb1355","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/nnm-2019-0398","article-title":"Nanoencapsulated dietary polyphenols for cancer prevention and treatment: successes and challenges","volume":"15","author":"Tabrez","year":"2020","journal-title":"Nanomedicine (London)"},{"issue":"4","key":"10.1016\/j.intimp.2026.116454_bb1360","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42682","article-title":"Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin","volume":"11","author":"Silva-Pinto","year":"2025","journal-title":"Heliyon"},{"issue":"13","key":"10.1016\/j.intimp.2026.116454_bb1365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26136265","article-title":"Silibinin anticancer effects through the modulation of the tumor immune microenvironment in triple-negative breast cancer","volume":"26","author":"Mishra","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116454_bb1370","doi-asserted-by":"crossref","first-page":"561","DOI":"10.12991\/jrespharm.1661054","article-title":"Pharmacological, medicinal and biological properties of flavonoids: a comprehensive review","volume":"29","author":"Yunuso\u011flu","year":"2024","journal-title":"J. Res. Pharm."},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb1375","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/oncolo\/oyad278","article-title":"First-in-human phase I study of minnelide in patients with advanced gastrointestinal cancers: safety, pharmacokinetics, pharmacodynamics, and antitumor activity","volume":"29","author":"Borazanci","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2026.116454_bb1380","doi-asserted-by":"crossref","unstructured":"Wang G, Guo H, Ren Y, Chen W, Wang Y, Li J, et al. Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma. Front. Pharmacol. 2023;Volume 14 - 2023.","DOI":"10.3389\/fphar.2023.1157433"},{"issue":"20","key":"10.1016\/j.intimp.2026.116454_bb1385","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2217\/fon-2021-1609","article-title":"A phase II trial of the super-enhancer inhibitor Minnelide\u2122 in advanced refractory adenosquamous carcinoma of the pancreas","volume":"18","author":"Skorupan","year":"2022","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb1390","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1039\/D4NP00066H","article-title":"Privileged natural product compound classes for anti-inflammatory drug development","volume":"42","author":"Choo","year":"2025","journal-title":"Nat. Prod. Rep."},{"issue":"14","key":"10.1016\/j.intimp.2026.116454_bb1395","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142209","article-title":"The role of natural products and their multitargeted approach to treat solid cancer","volume":"11","author":"Muhammad","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1096\/fj.201902143R","article-title":"Improving natural product research translation: From source to clinical trial","volume":"34","author":"Sorkin","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2026.116454_bb1405","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/bs.pmch.2019.01.001","article-title":"Natural product drug delivery: a special challenge?","volume":"58","author":"Press","year":"2019","journal-title":"Prog. Med. Chem."},{"issue":"9","key":"10.1016\/j.intimp.2026.116454_bb1410","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091169","article-title":"Application of nanotechnology and phytochemicals in anticancer therapy","volume":"16","author":"Kim","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1415","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1007\/s12672-025-02664-3","article-title":"Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics","volume":"16","author":"Ammar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb1420","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/cells14070488","article-title":"The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis","volume":"14","author":"Nishida","year":"2025","journal-title":"Cells [Internet]"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1425","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-024-01528-7","article-title":"Targeting inflammation as cancer therapy","volume":"17","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116454_bb1430","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/carcin\/bgad072","article-title":"Interplay between inflammasomes and PD-1\/PD-L1 and their implications in cancer immunotherapy","volume":"44","author":"Jiao","year":"2023","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.intimp.2026.116454_bb1435","doi-asserted-by":"crossref","first-page":"1040163","DOI":"10.3389\/fphar.2022.1040163","article-title":"Chronic inflammation, cancer development and immunotherapy","volume":"13","author":"Wen","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1440","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12964-025-02416-4","article-title":"Review: Progress of the NLRP3 inflammasome in tumours and perspectives for cholangiocarcinoma","volume":"23","author":"Zhuo","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"24","key":"10.1016\/j.intimp.2026.116454_bb1445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413689","article-title":"Therapeutic significance of NLRP3 inflammasome in cancer: friend or foe?","volume":"25","author":"Jalali","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116454_bb1450","article-title":"NLRPs and tumor: research progress from molecular mechanisms to clinical applications","author":"Song","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.116454_bb1455","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1682522","article-title":"Targeting radiotherapy-induced inflammation in cancer metastasis: insights into immune modulation, therapeutic opportunities and radiogenomics","volume":"15","author":"Lee","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116454_bb1460","doi-asserted-by":"crossref","unstructured":"Cao Y, Yi Y, Han C, Shi B. NF-\u03baB signaling pathway in tumor microenvironment. Front. Immunol. 2024;Volume 15 - 2024.","DOI":"10.3389\/fimmu.2024.1476030"},{"key":"10.1016\/j.intimp.2026.116454_bb1465","doi-asserted-by":"crossref","unstructured":"Owida HA, Abed AY, Altalbawy FMA, H M, Abbot V, Jakhonkulovna SM, et al. NLRP3 inflammasome-based therapies by natural products: a new development in the context of cancer therapy. Naunyn Schmiedeberg's Arch. Pharmacol. 2025;398(9):11073-92.DOI:https:\/\/doi.org\/10.1007\/s00210-025-04030-0.","DOI":"10.1007\/s00210-025-04030-0"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1470","doi-asserted-by":"crossref","first-page":"24753","DOI":"10.1038\/s41598-024-75805-3","article-title":"Inhibition of NLRP3 inflammasome contributes to paclitaxel efficacy in triple negative breast cancer treatment","volume":"14","author":"Balahura St\u0103mat","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116454_bb1475","article-title":"Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity","volume":"13","author":"Chen","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116454_bb1480","article-title":"Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment","volume":"6","author":"Lodi","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1485","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","article-title":"Decoding the spatiotemporal heterogeneity of tumor-associated macrophages","volume":"23","author":"Chu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb1490","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S1470-2045(24)00656-9","article-title":"Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation","volume":"26","author":"Morris","year":"2025","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb1495","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J. ImmunoTher. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb1500","article-title":"Synergistic anti-inflammatory effects of lipophilic grape seed proanthocyanidin and camellia oil combination in LPS-stimulated RAW264.7 cells","volume":"11","author":"Zhang","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.intimp.2026.116454_bb1505","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fphar.2019.01347","article-title":"Exploiting curcumin synergy with natural products using quantitative analysis of dose-effect relationships in an experimental in vitro model of osteoarthritis","volume":"10","author":"D\u2019Ascola","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116454_bb1510","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153309","article-title":"Synergistic anti-inflammatory effects of silibinin and thymol combination on LPS-induced RAW264.7 cells by inhibition of NF-\u03baB and MAPK activation","volume":"78","author":"Chen","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2026.116454_bb1515","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: The next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116454_bb1520","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: possibilities and limitations of the \"skeleton key approach\" from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116454_bb1525","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106055","article-title":"Polypharmacology: the science of multi-targeting molecules","volume":"176","author":"Kabir","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1530","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb1535","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine","volume":"14","author":"Ahmed","year":"2016","journal-title":"Genom. Proteom. Bioinf."},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb1540","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bulcan.2025.05.018","article-title":"Pharmacogenetics in oncology: Unveiling its potential in treatment personalization and beyond","volume":"112","author":"Tran","year":"2025","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.intimp.2026.116454_bb1545","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1521794","article-title":"Pharmacogenomics of TNF inhibitors","volume":"16","author":"Jan","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116454_bb1550","article-title":"Pharmacogenomics in solid tumors: a comprehensive review of genetic variability and its clinical implications","volume":"17","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"Cancers [Internet]"},{"issue":"2","key":"10.1016\/j.intimp.2026.116454_bb1555","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Therap."},{"issue":"5","key":"10.1016\/j.intimp.2026.116454_bb1560","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2026.116454_bb1565","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2217\/pgs.10.95","article-title":"Irinotecan pharmacogenomics","volume":"11","author":"Marsh","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116454_bb1570","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cts.13431","article-title":"Artificial intelligence in pharmacology research and practice","volume":"16","author":"van der Lee","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.116454_bb1575","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bcp.15930","article-title":"Artificial intelligence and machine learning for clinical pharmacology","volume":"90","author":"Ryan","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"603","key":"10.1016\/j.intimp.2026.116454_bb1580","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf3637","article-title":"Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data","volume":"13","author":"van der Lee","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116454_bb1585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008399","article-title":"Transfer learning enables prediction of CYP2D6 haplotype function","volume":"16","author":"McInnes","year":"2020","journal-title":"PLoS Comput. Biol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:10:40Z","timestamp":1790838640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926002985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":317,"alternative-id":["S1567576926002985"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116454","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs and natural bioactive products in modulation of inflammatory pathways in cancer: preclinical and clinical evidence of inflammasomes, cytokine networks, and macrophage polarization","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116454"}}